Status:
COMPLETED
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Neoplasms, Glandular and Epithelial
Diphtheria
Eligibility:
All Genders
11-17 years
Phase:
PHASE3
Brief Summary
Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) \[Types 6, 11, 16, 18\] Recombinant Vaccine) , when administered concomitantly with a combined diphtheria, tetanu...
Eligibility Criteria
Inclusion
- Must be healthy boys or girls, 11-17 years of age
- Must be a virgin with no intention of becoming sexually active during the study period
- Must have been properly vaccinated against diphtheria, tetanus and pertussis
Exclusion
- Must not have received a vaccine against diphtheria, tetanus and pertussis in the past 5 years
- Must not have received any prior human papillomavirus (HPV) vaccine or meningococcal vaccine
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
1042 Patients enrolled
Trial Details
Trial ID
NCT00325130
Start Date
April 1 2006
End Date
April 1 2007
Last Update
March 12 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.